Gerard J Criner, Jorge M Mallea, Muhanned Abu-Hijleh, Ashutosh Sachdeva, Ravi Kalhan, Christopher A Hergott, Donald R Lazarus, Richard A Mularski, Karel Calero, Michael F Reed, Stephanie Nsiah-Dosu, David Himes, Hiroshi Kubo, C Matthew Kinsey, Adnan Majid, D Kyle Hogarth, Philip V Kaplan, Amy Hajari Case, Samir S Makani, Tze-Ming Chen, Antoine Delage, Michael Zgoda, Ray W Shepherd
Rationale: Follow-up of patients with emphysema treated with endobronchial valves is limited to 3-12 months after treatment in prior reports. To date, no comparative data exist between treatment and control subjects with a longer follow-up. Objectives: To assess the durability of the Spiration Valve System (SVS) in patients with severe heterogeneous emphysema over a 24-month period. Methods: EMPROVE, a multicenter randomized controlled trial, presents a rigorous comparison between treatment and control groups for up to 24 months...
February 2024: Annals of the American Thoracic Society